T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI

Lung Cancer

Volumn 76, Issue 1, 2012, Pages 129-130

  Uramoto, Hidetaka ^a   Yano, Seiji ^b   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; EGFR mutation; Lung cancer; Prognosis; Resistance; T790M

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); GENE DELETION; GENE MUTATION; HUMAN; JAPANESE; LETTER; LUNG ADENOCARCINOMA; POINT MUTATION; PRIORITY JOURNAL;

HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84858007882     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.01.010     Document Type: Letter

References (5)

1. Suda K, Tomizawa K, Osada H, Maehara Y, Yatabe Y, Sekido Y, et al. Conversion from the " oncogene addiction" to " drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer, in press.
2. Toyooka S., Kiura K., Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 2005, 352:2136.
3. Chmielecki J., Foo J., Oxnard G.R., Hutchinson K., Ohashi K., Somwar R., et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011, 3:90ra59.
4. Uramoto H., Shimokawa H., Hanagiri T., Kuwano M., Ono M. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 2011, 73:361-365.
5. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.